# EDGAR Filing Document

**Accession Number:** 0001736730
**File Stem:** 0001736730-26-000018
**Filing Date:** 2026-3
**Character Count:** 34109
**Document Hash:** 772b578e2b67d9b39a4a035f39807310
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001736730-26-000018.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001736730-26-000018

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**EFFECTIVENESS DATE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Camp4 Therapeutics Corp
- **CENTRAL INDEX KEY:** 0001736730
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294048
- **FILM NUMBER:** 26726332

**BUSINESS ADDRESS:**
- **STREET 1:** ONE KENDALL SQUARE
- **STREET 2:** BUILDING 1400 WEST, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-651-8867

**MAIL ADDRESS:**
- **STREET 1:** ONE KENDALL SQUARE
- **STREET 2:** BUILDING 1400 WEST, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**As filed with the Securities and Exchange Commission on March 5, 2026**

**Registration No. 333-**

___________________________________

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

___________________________________

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

___________________________________

**CAMP4 THERAPEUTICS CORPORATION**

**(Exact name of registrant as specified in its charter)**

___________________________________

---

| | |
|:---|:---|
| **Delaware** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**81-1152476** |
| **(State or other jurisdiction of** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(I.R.S. Employer** |
| **incorporation or organization)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Identification No.)** |
| **One Kendall Square** |  |
| **Building 1400 West, 3rd Floor** |  |
| **Cambridge, Massachusetts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**02139** |
| **(Address of Principal Executive Offices)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(Zip Code)** |

---

**CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan<br>CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan<br>Inducement Option Award Agreements<br>(Full titles of the plans)**

___________________________________

**Josh Mandel-Brehm**

**Chief Executive Officer**

**CAMP4 Therapeutics Corporation**

**One Kendall Square, Building 1400 West, 3rd Floor**

**Cambridge, Massachusetts 02139**

**(Name and address of agent for service)**

**(617) 651-8867**

**(Telephone number, including area code, of agent for service)**

___________________________________

***Please send a copy of all communications to:***

**Thomas J. Danielski**

**Ropes & Gray LLP**

**Prudential Tower**

**800 Boylston Street**

**Boston, Massachusetts 02199-3600**

**617-951-7000**

___________________________________

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer, "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;Large accelerated filer | □ | Accelerated filer | □ |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
| | | Emerging growth company | ⌧ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

 **EXPLANATORY NOTE**

This Registration Statement on Form S-8 (the "Registration Statement"), as it relates to the 2024 Equity Incentive Plan (the "2024 Plan") and the 2024 Employee Stock Purchase Plan (the "ESPP") of CAMP4 Therapeutics Corporation (the "Registrant"), is being filed with the Securities and Exchange Commission (the "Commission") for the purpose of registering (i) 2,595,130 additional shares of common stock, $0.0001 par value per share ("Common Stock"), under the 2024 Plan pursuant to the provisions of the 2024 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2024 Plan on January 1, 2026, and (ii) 519,026 additional shares of Common Stock under the ESPP pursuant to the provisions of the ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the ESPP on January 1, 2026. Pursuant to General Instruction E to Form S-8, the Registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of the following Registration Statements on Form S-8 filed by the Registrant with the Commission relating to the 2024 Plan and the ESPP.

---

| | |
|:---|:---|
| **<u>SEC File No.</u>** | **<u>Date Filed with the Commission</u>** |
| 333-282676 | <u>[October 16, 2024](https://www.sec.gov/Archives/edgar/data/1736730/000110465924109144/tm2426234d1_s8.htm)</u> |
| 333-286172 | <u>[March](https://www.sec.gov/Archives/edgar/data/1736730/000173673025000023/a20250327forms-8.htm)[27, 2025](https://www.sec.gov/Archives/edgar/data/1736730/000173673025000023/a20250327forms-8.htm)</u> |

---

This Registration Statement additionally relates to 188,000 shares of Common Stock issuable upon the vesting, exercise and settlement of certain stock option inducement award grants made by the Registrant to employees of the Registrant, in each case in reliance on and pursuant to the employment inducement exemption under Rule 5635(c)(4) of The Nasdaq Stock Market Rules.

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

As permitted by Rule 428(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the employees to whom stock options were issued. Such documents are not being filed with the Commission as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by the Registrant with the Commission are incorporated herein by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, <u>[filed on March](https://www.sec.gov/ix?doc=/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm)[5](https://www.sec.gov/ix?doc=/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm)[, 202](https://www.sec.gov/ix?doc=/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm)[6](https://www.sec.gov/ix?doc=/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm)</u>;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.the description of the Registrant's Common Stock contained in <u>[Exhibit 4.](https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/exhibit41-descriptionofreg.htm)[1](https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/exhibit41-descriptionofreg.htm)</u> to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on March 5, 2026, including any amendments or reports filed for the purpose of updating such description.

All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated herein by reference herein and to be part hereof from the date of filing of such reports and documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this

------

Registration Statement to the extent that a statement contained herein or in any subsequently filed report or document which also is incorporated or is deemed to be incorporated by reference herein modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

As permitted by Section 102(b)(7) of the General Corporation Law of the State of Delaware (the "DGCL"), the Registrant's restated certificate of incorporation (the "Restated Charter") includes a provision to eliminate the personal liability of the Registrant's directors and officers for monetary damages for breach of their fiduciary duties as directors, subject to certain exceptions. In addition, the Restated Charter and amended and restated bylaws provide that the Registrant is required to indemnify its officers and directors under certain circumstances, including those circumstances in which indemnification would otherwise be discretionary, and the Registrant is required to advance expenses to its officers and directors as incurred in connection with proceedings against them for which they may be indemnified, in each case except to the extent that the DGCL prohibits the elimination or limitation of liability of directors or officers for breaches of fiduciary duty.

Section 145(a) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interest of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person's conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person's conduct was unlawful.

Section 145(b) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

------

The Registrant has entered into indemnification agreements with its directors and executive officers. These indemnification agreements provide broader indemnity rights than those provided under the DGCL and the Restated Charter. These indemnification agreements are not intended to deny or otherwise limit third-party or derivative suits against the Registrant or its directors or officers, but to the extent a director or officer were entitled to indemnity or contribution under the indemnification agreement, the financial burden of a third-party suit would be borne by the Registrant, and the Registrant would not benefit from derivative recoveries against the director or officer. Such recoveries would accrue to the Registrant's benefit but would be offset by its obligations to the director or officer under the indemnification agreement.

The Registrant maintains directors' and officers' liability insurance for the benefit of its directors and officers.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | |
| 4.1 | <u>[Fifth Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the](https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_ex3-1.htm)[Commission](https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_ex3-1.htm)[on October 15, 2024 and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_ex3-1.htm)</u> |
| 4.2 | <u>[Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed with the](https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_ex3-2.htm)[C](https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_ex3-2.htm)[ommi](https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_ex3-2.htm)[ssion](https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_ex3-2.htm)[on October 15, 2024 and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_ex3-2.htm)</u> |
| 4.3 | <u>[CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan (previously filed as Exhibit 4.2 to the Registrant's Registration Statement on Form S-8 filed with the](https://www.sec.gov/Archives/edgar/data/1736730/000110465924109144/tm2426234d1_ex4-2.htm)[Commission](https://www.sec.gov/Archives/edgar/data/1736730/000110465924109144/tm2426234d1_ex4-2.htm)[on October 16, 2024 and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1736730/000110465924109144/tm2426234d1_ex4-2.htm)</u> |
| 4.4 | <u>[CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan (previously filed as Exhibit 4.3 to the Registrant's Registration Statement on Form S-8 filed with the SEC on October 16, 2024 and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1736730/000110465924109144/tm2426234d1_ex4-3.htm)</u> |
| 4.5 | <u>[Form of Inducement Option Award Agreement (previously filed as Exhibit 10.22 to the Registrant's Annual Report on Form 10-K filed with the Commission on March 5, 2026 and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/exhibit1022-formofinduceme.htm)</u> |
| 5.1\* | <u>[Opinion of Ropes & Gray LLP.](exhibit51-opiniontosx8eipi.htm)</u> |
| 23.1\* | <u>[Consent of Ernst & Young LLP.](exhibit231-sx8consent.htm)</u> |
| 23.2\* | <u>[Consent of Ropes & Gray LLP (included in the opinion filed as Exhibit 5.1).](exhibit51-opiniontosx8eipi.htm)</u> |
| 24.1\* | <u>[Powers of Attorney (included on the signature page in Part II).](#ie5d8c42f97bd4430acf5b088860201ae_1575)</u> |
| 107\* | <u>[Filing Fee Table.](exfilingfees.htm)</u> |

---

\* Filed herewith.

**Item 9. Undertakings.**

(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the SEC pursuant to Rule

------

424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

*provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) above shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities

Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**Signatures**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Massachusetts, on this 5th day of March, 2026.

---

| | |
|:---|:---|
| **CAMP4 THERAPEUTICS CORPORATION** | **CAMP4 THERAPEUTICS CORPORATION** |
| By: | /s/ Josh Mandel-Brehm |
|  | Josh Mandel-Brehm<br>President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Josh Mandel-Brehm and Kelly Gold, and each of them singly, his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by CAMP4 Therapeutics Corporation and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Josh Mandel-Brehm | President, Chief Executive Officer and Director | March 5, 2026 |
| /s/ Josh Mandel-Brehm | President, Chief Executive Officer and Director | March 5, 2026 |
| Josh Mandel-Brehm | *(Principal Executive Officer)* |  |
| /s/ Kelly Gold | Chief Financial Officer | March 5, 2026 |
| /s/ Kelly Gold | Chief Financial Officer | March 5, 2026 |
| Kelly Gold | *(Principal Financial Officer and Principal Accounting Officer)* |  |
| /s/ Douglas Williams | Director and Chair&nbsp;&nbsp;&nbsp;&nbsp; | March 5, 2026 |
| Douglas Williams, PhD |  | March 5, 2026 |
| /s/ Michael Higgins | Director | March 5, 2026 |
| Michael Higgins |  | March 5, 2026 |
| /s/ Steven Holtzman | Director | March 5, 2026 |
| Steven Holtzman |  | March 5, 2026 |
| /s/ Amir Nashat | Director | March 5, 2026 |
| Amir Nashat, ScD |  | March 5, 2026 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Andrew Schwab | Director | March 5, 2026 |
| Andrew Schwab | | March 5, 2026 |
| /s/ Murray Stewart | Director | March 5, 2026 |
| Murray Stewart, DM FRCP | | March 5, 2026 |
| /s/ Richard Young | Director | March 5, 2026 |
| Richard Young, PhD | | March 5, 2026 |

---

## Exhibit 5.1

![image_0.jpg](image_0.jpg)

ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM

March 5, 2026

CAMP4 Therapeutics Corporation

One Kendall Square, Building 1400 West, 3rd Floor

Cambridge, MA 02139

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the "<u>Registration Statement</u>"), filed by CAMP4 Therapeutics Corporation, a Delaware corporation (the "<u>Company</u>"), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), for the registration of an aggregate of (i) 3,114,156 shares of common stock, $0.0001 par value per share (the "<u>Common Stock</u>") of the Company (the "<u>Plan Shares</u>") issuable under the Company's 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan (each, a "<u>Plan</u>" and collectively, the "<u>Plans</u>"), and (ii) an aggregate of 188,000 shares of Common Stock (the "<u>Inducement Shares</u>" and, together with the Plan Shares, the "<u>Shares</u>") issuable upon the exercise of certain stock options granted by the Company to certain employees in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement to each such person entering into employment with the Company (collectively, the "<u>Inducement Grants</u>").

We are familiar with the actions taken by the Company in connection with the adoption of the Plans and the award of the Inducement Grants. We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the applicable Plan or the Inducement Grants, as applicable, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Ropes & Gray LLP

Ropes & Gray LLP

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan, the CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan and Inducement Option Award Agreements of our report dated March 5, 2026, with respect to the consolidated financial statements of CAMP4 Therapeutics Corporation, included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 5, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107**

**Calculation of Filing Fee Tables**

Form S-8

(Form Type)

CAMP4 Therapeutics Corporation

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount**<br>**Registered**<sup>(1)</sup> | **Proposed Maximum<br>Offering Price Per Unit** | **Maximum<br>Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan – Common Stock, $0.0001 par value per share | Other – 457(c) and 457(h) | 2,595,130 shares<sup>(2)</sup> | $4.52495<sup>(3)</sup> | $11742833.49 | 0.0001381 | $1621.69 |
| Equity | CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan – Common Stock, $0.0001 par value per share | Other – 457(c) and 457(h) | 519,026 shares<sup>(4)</sup> | $4.52495<sup>(3)</sup> | $2348566.70 | 0.0001381 | $324.34 |
| Equity | Inducement Option Award Agreement – Common Stock, $0.0001 par value per share | 457(h) | 80,000 shares<sup>(5)</sup> | $4.39<sup>(6)</sup> | $351200.00 | 0.0001381 | $48.50 |
| Equity | Inducement Option Award Agreement – Common Stock, $0.0001 par value per share | 457(h) | 92,000 shares<sup>(5)</sup> | $6.01<sup>(6)</sup> | $552920.00 | 0.0001381 | $76.46 |
| Equity | Inducement Option Award Agreement – Common Stock, $0.0001 par value per share | 457(h) | 8,000 shares<sup>(5)</sup> | $5.78<sup>(6)</sup> | $46240.00 | 0.0001381 | $6.39 |
| Equity | CAMP4 Therapeutics Corporation Inducement Option Award Agreements – Common Stock, $0.0001 par value per share | 457(h) | 8,000 shares<sup>(5)</sup> | $3.85<sup>(6)</sup> | $30800.00 | 0.0001381 | $4.25 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** |  |  | $15072560.19 |  | $2081.53 |
|  | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |  |
|  | **Net Fee Due** | **Net Fee Due** |  |  |  |  | $2081.53 |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Act") this Registration Statement also covers such additional shares of common stock, par value $0.0001 per share ("Common Stock") as may be issued to prevent dilution from stock splits, stock dividends, recapitalization and other similar transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Represents 2,595,130 additional shares of Common Stock reserved for issuance under the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan (the "2024 Plan") on January 1, 2026, pursuant to an "evergreen" provision contained in the 2024 Plan, which provides that on January 1<sup>st</sup> of each year during the term of the 2024 Plan beginning in 2025, the number of shares of Common Stock available for issuance under the 2024 Plan will automatically increase in an amount equal to the lesser of (A) five percent of the number of shares of Common Stock outstanding as of the immediately preceding December 31<sup>st</sup> and (B) the number of shares of Common Stock determined by the board of directors of the Registrant on or prior to such date for such year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Act based on the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Market on February 26, 2026 to be $4.8299 and $4.22, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Represents 519,026 additional shares of Common Stock reserved for issuance under the CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan (the "ESPP") on January 1, 2026, pursuant to an "evergreen" provision contained in the ESPP, which provides that on January 1<sup>st</sup> of each year during the term of the ESPP beginning in 2025, the number of shares of Common Stock available for issuance under the ESPP will automatically increase in an amount equal to the lesser of (A) one percent of the number of shares of Common Stock outstanding as of the immediately preceding December 31<sup>st</sup> and (B) the number of shares of Common Stock determined by the board of directors of the Registrant on or prior to such date for such year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Consists of shares of common stock of the Registrant issuable under new hire inducement stock option awards as an inducement material to entry into employment with the Registrant in accordance with Nasdaq Listing Rule 5635(c)(4).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) under the Act based on the exercise price of the inducement stock option, which is equal to the closing price of the Registrant's Common Stock on the Nasdaq Global Market on the applicable grant date.